Biogen trading on hold ahead of FDA meeting on Alzheimer’s drug

Trading in Biogen (BIIB) – Get Report The drugmaker was stopped Friday before a meeting of the US Food and Drug Administration Advisory Committee on the Treatment of Experimental Alzheimer’s Disease.

The FDA panel of outside consultants will discuss whether aducanumab is an effective treatment for Alzheimer’s disease and whether to recommend drug withdrawal.

The FDA is not required to follow the advice of an advisory committee, but it usually does.

The panel has been the source of some controversy after the FDA re-appointed a member citing a conflict of interest.


Leave a Reply

Your email address will not be published.